Jennifer Fazzari1, Jesse Sidhu1, Shreya Motkur1, Mark Inman2, Norman Buckley3, Mark Clemons4,5, Lisa Vandermeer5, Gurmit Singh1,3. 1. Department of Pathology & Molecular Medicine, McMaster University, Hamilton, Ontario, Canada. 2. Department of Medicine, McMaster University, Hamilton, Ontario, Canada. 3. Michael G. DeGroote Institute for Pain Research and Care, McMaster University, Hamilton, Ontario, Canada. 4. Department of Medicine, Division of Medical Oncology, The Ottawa Hospital, Ottawa, Canada. 5. Cancer Research Program, Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Canada.
Abstract
BACKGROUND AND AIM: Cancers originating in the breast, lung and prostate often metastasize to the bone, frequently resulting in cancer-induced bone pain that can be challenging to manage despite conventional analgesic therapy. This exploratory study's aim was to identify potential biomarkers associated with cancer-induced pain by examining a sample population of breast cancer patients undergoing bisphosphonate therapy. METHODS: A secondary analysis of the primary study was performed to quantify serum cytokine levels for correlation to pain scores. Cytokines with statistically significant correlations were then input into a stepwise regression analysis to generate a predictive equation for a patient's pain severity. In an effort to find additional potential biomarkers, correlation analysis was performed between these factors and a more comprehensive panel of cytokines and chemokines from breast, lung, and prostate cancer patients. RESULTS: Statistical analysis identified nine cytokines (GM-CSF, IFNγ, IL-1β, IL-2, IL-4, IL-5, IL-12p70, IL-17A, and IL-23) that had significant negative correlations with pain scores and they could best predict pain severity through a predictive equation generated for this specific evaluation. After performing a correlation analysis between these factors and a larger panel of cytokines and chemokines, samples from breast, lung and prostate patients showed distinct correlation profiles, highlighting the clinical challenge of applying pain-associated cytokines related to more defined nociceptive states, such as arthritis, to a cancer pain state. CONCLUSION: Exploratory analyses such as the ones presented here will be a beneficial tool to expand insights into potential cancer-specific nociceptive mechanisms and to develop novel therapeutics.
BACKGROUND AND AIM: Cancers originating in the breast, lung and prostate often metastasize to the bone, frequently resulting in cancer-induced bone pain that can be challenging to manage despite conventional analgesic therapy. This exploratory study's aim was to identify potential biomarkers associated with cancer-induced pain by examining a sample population of breast cancer patients undergoing bisphosphonate therapy. METHODS: A secondary analysis of the primary study was performed to quantify serum cytokine levels for correlation to pain scores. Cytokines with statistically significant correlations were then input into a stepwise regression analysis to generate a predictive equation for a patient's pain severity. In an effort to find additional potential biomarkers, correlation analysis was performed between these factors and a more comprehensive panel of cytokines and chemokines from breast, lung, and prostate cancer patients. RESULTS: Statistical analysis identified nine cytokines (GM-CSF, IFNγ, IL-1β, IL-2, IL-4, IL-5, IL-12p70, IL-17A, and IL-23) that had significant negative correlations with pain scores and they could best predict pain severity through a predictive equation generated for this specific evaluation. After performing a correlation analysis between these factors and a larger panel of cytokines and chemokines, samples from breast, lung and prostate patients showed distinct correlation profiles, highlighting the clinical challenge of applying pain-associated cytokines related to more defined nociceptive states, such as arthritis, to a cancer pain state. CONCLUSION: Exploratory analyses such as the ones presented here will be a beneficial tool to expand insights into potential cancer-specific nociceptive mechanisms and to develop novel therapeutics.
Authors: Edward Chow; Carlo DeAngelis; Bingshu E Chen; Azar Azad; Ralph M Meyer; Carolyn Wilson; Marc Kerba; Andrea Bezjak; Paula Wilson; Abdenour Nabid; Jonathan Greenland; Gareth Rees; Reinhold Vieth; Rebecca K S Wong; Peter Hoskin Journal: Radiother Oncol Date: 2015-03-14 Impact factor: 6.280
Authors: Christina L Addison; Nathaniel Bouganim; John Hilton; Lisa Vandermeer; Susan Dent; Eitan Amir; Sean Hopkins; Iryna Kuchuk; Roanne Segal; Xinni Song; Stan Gertler; Sasha Mazzarello; George Dranitsaris; Daylily Ooi; Gregory Pond; Mark Clemons Journal: Breast Cancer Res Treat Date: 2014-03-18 Impact factor: 4.872
Authors: A B Niculescu; H Le-Niculescu; D F Levey; K Roseberry; K C Soe; J Rogers; F Khan; T Jones; S Judd; M A McCormick; A R Wessel; A Williams; S M Kurian; F A White Journal: Mol Psychiatry Date: 2019-02-12 Impact factor: 15.992
Authors: Jami L Saloman; Gong Tang; Kimberly M Stello; Kristen E Hall; Xianling Wang; Samer AlKaade; Peter A Banks; Randall E Brand; Darwin L Conwell; Gregory A Coté; Christopher E Forsmark; Timothy B Gardner; Andres Gelrud; Michele D Lewis; Stuart Sherman; Adam Slivka; David C Whitcomb; Dhiraj Yadav Journal: Pancreatology Date: 2021-09-30 Impact factor: 3.996
Authors: Marta Diaz-delCastillo; Rebecca E Andrews; Aritri Mandal; Thomas L Andersen; Andrew D Chantry; Anne-Marie Heegaard Journal: Cancers (Basel) Date: 2021-03-30 Impact factor: 6.639